Credit Suisse’s ClearPoint Neuro CLPT Stock Holding History

Credit Suisse’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10	Closed	–	–	4067
2022 Q2	$0	Buy	+10	New	+$102	﹤0.01%	3977

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CCM

Conway Capital Management Burbank, California $214M AUM 22.99% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Credit Suisse's CLPT Position: Q3 2022 in Review

Credit Suisse sold out of ClearPoint Neuro (CLPT) in Q3 2022, closing a stake of 10 shares.

Credit Suisse first reported a position in CLPT in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 56 funds tracked by Wall St. Rank hold CLPT as of Q3 2022.

Credit Suisse reported no remaining ClearPoint Neuro position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 10 ClearPoint Neuro shares in Q3 2022.
Credit Suisse first reported a position in ClearPoint Neuro in Q2 2022 and held it in 1 quarter.
Credit Suisse's ClearPoint Neuro position peaked at $0 in Q2 2022.
56 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.